Masayoshi Yamaguchi, Ph.D, IOM, FAOE, DDG, DG, is Professor, Cancer Biology, University of Hawaii Cancer Center, University of Hawaii at Manoa (2019); Visiting Professor, Department of Pathology and Laboratory Medicine, David Gefen School of Medicine, University of California, Los Angeles (UCLA) (2017); Adjunct Professor, University of Hawaii Cancer Center (2017-2018); Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-2016); Visiting Professor, Department of Medicine, Baylor Medical College, Houston, USA (2012-2013); Visiting Professor, Department of Medicine, Emory University School of Medicine (2007-2011); Professor, Graduate School of Nutritional Sciences, University of Shizuoka, Shizuoka, Japan
Masayoshi Yamaguchi, Ph.D, IOM, FAOE, DDG, DG, is Professor, Cancer Biology, University of Hawaii Cancer Center, University of Hawaii at Manoa (2019); Visiting Professor, Department of Pathology and Laboratory Medicine, David Gefen School of Medicine, University of California, Los Angeles (UCLA) (2017); Adjunct Professor, University of Hawaii Cancer Center (2017-2018); Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-2016); Visiting Professor, Department of Medicine, Baylor Medical College, Houston, USA (2012-2013); Visiting Professor, Department of Medicine, Emory University School of Medicine (2007-2011); Professor, Graduate School of Nutritional Sciences, University of Shizuoka, Shizuoka, Japan (1992-2007). He is engaged in the fields of endocrinology and cell signaling since 1971, and these researches are developed in the aspects of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology and toxicology. He discovered two novel proteins (genes), which were named a regucalcin, a cell signaling suppressor (1978), and RGPR-p117, a regucalcin gene promoter-related transcription factor (2001). Dr. Yamaguchi generated regucalcin transgenic rats, which were registered as international patents including USA, EU and Japan, and this animal model was found to induce osteoporosis and hyperlipidemia. Moreover, he proposed the potential role of regucalcin as a key suppressor in human carcinogenesis. Currently, Dr. Yamaguchi has an interesting in the fields of regucalcin biomedical research, cancer biology, and bone biology and osteoporosis treatment. Since 1974, Dr. Yamaguchi published over 550 English articles in professional journals with peer-review, and registered 23 national and international patents. Dr. Yamaguchi serviced as Editorial Board Members in 90 Journals thus far. Dr. Yamaguchi was listed in various biographies; Who’s Who in the World (2005, Marquis Who’s Who, USA), Who’s Who in Sciences and Engineering (2004, Marquis Who’s Who, USA), and International Biographical Dictionary (2006, IBC, England). Dr. Yamaguchi received “The 2017 Albert Nelson Marquis Lifetime Achievement Award” （Marquis Who's Who, USA).
Wayman Wendell Cheatham, M.D., FACE, board certified in endocrinology and metabolism, is Director of Research Administration and External Research Affairs for the Bureau of Medicine and Surgery of the United States Navy. Dr. Cheatham's roles are to ensure the organization of and access to information forappropriate execution of policy and oversight within Naval Medical Research. He also oversees adherence to standards of research integrity and ethics. He serves as the Executive Secretary of the Armed Services Biomedical Research, Evaluation and Management (ASBREM) Community of Interest for Department of Defense components that oversee, fund or execute medical research. Dr. Cheatham served as
Wayman Wendell Cheatham, M.D., FACE, board certified in endocrinology and metabolism, is Director of Research Administration and External Research Affairs for the Bureau of Medicine and Surgery of the United States Navy. Dr. Cheatham's roles are to ensure the organization of and access to information forappropriate execution of policy and oversight within Naval Medical Research. He also oversees adherence to standards of research integrity and ethics. He serves as the Executive Secretary of the Armed Services Biomedical Research, Evaluation and Management (ASBREM) Community of Interest for Department of Defense components that oversee, fund or execute medical research. Dr. Cheatham served as the senior executive in charge of research for one of the World's largest pharmaceutical companies. Dr. Cheatham is published in prominent research journals and is proficient in research protocol design. His current research interests include pancreatic islet function and regeneration, insulin action, and metabolic basis of vascular dysfunction.
Dr. Mario Barbagallo was born on March 16, 1959, Palermo, Italy. Full Professor of Internal Medicine and Geriatrics, University of Palermo. Head of the Geriatric Unit, University Hospital of Palermo, Italy.Ph.D. in Physiology, University of Rome in 1989.Visiting scientist at the Cardiovascular Center, Cornell University Medical Center, New York, NY, USA in 1991 1992. Visiting scientist, at the Department of Physiology, University of Alberta, Edmonton, Canada, in 1992. Fulbright Scholar and Visiting Professor at the Division of Endocrinology and Hypertension, Wayne State University, Detroit, MI, USA in 1994-1995. Visiting Professor at the Capitol University of Medical Sciences, Bejing (China) in
Dr. Mario Barbagallo was born on March 16, 1959, Palermo, Italy. Full Professor of Internal Medicine and Geriatrics, University of Palermo. Head of the Geriatric Unit, University Hospital of Palermo, Italy.Ph.D. in Physiology, University of Rome in 1989.Visiting scientist at the Cardiovascular Center, Cornell University Medical Center, New York, NY, USA in 1991 1992. Visiting scientist, at the Department of Physiology, University of Alberta, Edmonton, Canada, in 1992. Fulbright Scholar and Visiting Professor at the Division of Endocrinology and Hypertension, Wayne State University, Detroit, MI, USA in 1994-1995. Visiting Professor at the Capitol University of Medical Sciences, Bejing (China) in 1994. His research interests include Diabetes and Hypertension, Diabetes and cognitive decline, Insulin resistance, Magnesium, Diabetes in the elderly, Frailty.
Dr. Pradeep Mally is Associate Professor of Pediatrics at the New York University School of Medicine. He is the Chief of the Division of Newborn Medicine and has direct oversight over 2 Regional Neonatal Center′s at NYU Langone Medical Center and Bellevue Hospital Center in New York , with a combined bed capacity of 55. Dr. Mally is also the director of the neonatal-perinatal fellowship program at NYU School of Medicine and is the president of the New York perinatal society. Dr. Mally has published extensively on topics related to late preterm infants, neonatal diabetes and sepsis, use of
Dr. Pradeep Mally is Associate Professor of Pediatrics at the New York University School of Medicine. He is the Chief of the Division of Newborn Medicine and has direct oversight over 2 Regional Neonatal Center′s at NYU Langone Medical Center and Bellevue Hospital Center in New York , with a combined bed capacity of 55. Dr. Mally is also the director of the neonatal-perinatal fellowship program at NYU School of Medicine and is the president of the New York perinatal society. Dr. Mally has published extensively on topics related to late preterm infants, neonatal diabetes and sepsis, use of near Infra-Red Spectroscopy [NIRS] in clinical neonatology and blood transfusion and necrotizing enterocolitis. His research interest includes the use of near infra-red spectroscopy in clinical neonatology, use of newer mode of neonatal ventilation [NAVA] in clinical practice and acute and long term morbidities in late premature neonates.
Fernando Ovalle, MD, FACE, is a Professor of Medicine at the University of Alabama at Birmingham (UAB) School of Medicine. In addition to maintaining a large and busy clinical practice, he serves as the Director of the Multidisciplinary Comprehensive Diabetes Clinic, and Director of Diabetes and Glycemic Control Programs at UAB Hospital. Also, he is the Director of the Diabetes & Endocrine Clinical Research Unit, and the Program Director for the Division of Diabetes, Endocrinology, and Metabolism at UAB. His research interests Clinical diabetes, Therapy of diabetes, Classification of diabetes, High insulin requirements, Severe insulin resistance, Lipodystrophy in diabetes, Autoimmune
Fernando Ovalle, MD, FACE, is a Professor of Medicine at the University of Alabama at Birmingham (UAB) School of Medicine. In addition to maintaining a large and busy clinical practice, he serves as the Director of the Multidisciplinary Comprehensive Diabetes Clinic, and Director of Diabetes and Glycemic Control Programs at UAB Hospital. Also, he is the Director of the Diabetes & Endocrine Clinical Research Unit, and the Program Director for the Division of Diabetes, Endocrinology, and Metabolism at UAB. His research interests Clinical diabetes, Therapy of diabetes, Classification of diabetes, High insulin requirements, Severe insulin resistance, Lipodystrophy in diabetes, Autoimmune diabetes, Monogenic diabetes.
Dr Jones is Head of Department of Diabetes and Endocrinology, Princess Margaret Hospital for Children, Perth, Clinical Professor at the Institute for Child Health Research, University of Western Australia and holds an NHMRC Practitioner Fellowship. Dr Jones received his paediatric training in Australia and the UK and his post doctoral training at Yale University, USA. He is Chair of the Australasian Paediatric Endocrine Group′s Children′s Diabetes Network and leads a number of national trials. Dr Jones has a strong clinical research interest in diabetes, in particular hypoglycaemia, insulin therapy, exercise, technology and complications, is director of the NHMRC/JDRF
Dr Jones is Head of Department of Diabetes and Endocrinology, Princess Margaret Hospital for Children, Perth, Clinical Professor at the Institute for Child Health Research, University of Western Australia and holds an NHMRC Practitioner Fellowship. Dr Jones received his paediatric training in Australia and the UK and his post doctoral training at Yale University, USA. He is Chair of the Australasian Paediatric Endocrine Group′s Children′s Diabetes Network and leads a number of national trials. Dr Jones has a strong clinical research interest in diabetes, in particular hypoglycaemia, insulin therapy, exercise, technology and complications, is director of the NHMRC/JDRF funded Centre for Research Excellence in diabetes translational research, and leads a research team based at the Institute of Child Health Research and Princess Margaret Hospital for Children.
With an initial professional emphasis on reproductive physiology and endocrinology, Clayton holds a patent for a substance and process for disturbing the inheritance pattern of ion channelopathic disorders. He served as the Director of Clinical Research and Development for a small biotech company working to bring improved assisted reproductive technologies to market. Clayton serendipitously received glucose clamping training from a leading authority on diabetes who was, at the time, an associate professor of medicine at Harvard Medical School. This led Clayton to refocus his research interests on metabolic disturbances related to diabetes and obesity and early clinical research models that
With an initial professional emphasis on reproductive physiology and endocrinology, Clayton holds a patent for a substance and process for disturbing the inheritance pattern of ion channelopathic disorders. He served as the Director of Clinical Research and Development for a small biotech company working to bring improved assisted reproductive technologies to market. Clayton serendipitously received glucose clamping training from a leading authority on diabetes who was, at the time, an associate professor of medicine at Harvard Medical School. This led Clayton to refocus his research interests on metabolic disturbances related to diabetes and obesity and early clinical research models that offer predictive signals of safety or efficacy. These empower better decision making earlier in the drug development process.Clayton hasheld executive positions at global contract research organizationsleading some of the most robust, large-scale, therapeutically focused, early phase clinical research programs. Clayton Dehn's research focus on Glucose clamps as measures of insulin sensitivity, beta cell sensitivity, or time-action profiling of insulin products. Flow Mediated Dilation as a measure of endothelial function that is highly correlated to cardiovascular outcomes. Measures and models of glucose dysregulation including Graded Glucose Infusions, Intravenous Glucose Tolerance Testing, Insulin Tolerance Testing, Oral Glucose Tolerance Testing, Mixed-Meal Glucose Tolerance Testing, Maximum Pancreatic Stimulation Testing.
Prof. Kyuzi Kamoi was born August 28, 1943 in Tokyo, Japan. He received his MD in 1970 and his MSD in 1982, both from the Medical School of Niigata University, Niigata, Japan. He has received the following certificates: Japan Medical Diplomat (1970), Japan Board of Diabetes Mellitus (1990), Japan Board of Endocrinology and Metabolism (1991), Certified Diabetes Mellitus Educator (1993), Certified Endocrine Educator (2004). From 1980 to 2010 he was Chief of Internal Medicine, and from 2002 until 2010 the Director of Center of Diabetes Mellitus and Endocrine Disease at Nagaoka Red Cross Hospital, Japan. Since 2010 to the present
Prof. Kyuzi Kamoi was born August 28, 1943 in Tokyo, Japan. He received his MD in 1970 and his MSD in 1982, both from the Medical School of Niigata University, Niigata, Japan. He has received the following certificates: Japan Medical Diplomat (1970), Japan Board of Diabetes Mellitus (1990), Japan Board of Endocrinology and Metabolism (1991), Certified Diabetes Mellitus Educator (1993), Certified Endocrine Educator (2004). From 1980 to 2010 he was Chief of Internal Medicine, and from 2002 until 2010 the Director of Center of Diabetes Mellitus and Endocrine Disease at Nagaoka Red Cross Hospital, Japan. Since 2010 to the present he has been Professor of Niigata Prefecture University. Research interests include Diaebetic patients with type 2 may be due to a decreased function of incretion hormones. His specially is a disorders of vasopressin.
Dr. Silver is the Directorof Vanderbilt Nutrition and Diet Assessment Core Lab. Her research is an integral component of an emerging dynamic translational research program in obesity, the metabolic syndrome and diabetes. Her studies target modulating the macronutrient composition of dietary intakes in obese adults and children, specifically dietary fat and fatty acids, to investigate effects on the pathophysiology, risk factors and outcomes of diabetes, obesity and related comorbidities. She designs translational dietary food and supplement interventions to further understand effects on metabolism and energy homeostasis, body composition, insulin resistance, oxidative stress and inflammation. Dr. Silver has completed several randomized
Dr. Silver is the Directorof Vanderbilt Nutrition and Diet Assessment Core Lab. Her research is an integral component of an emerging dynamic translational research program in obesity, the metabolic syndrome and diabetes. Her studies target modulating the macronutrient composition of dietary intakes in obese adults and children, specifically dietary fat and fatty acids, to investigate effects on the pathophysiology, risk factors and outcomes of diabetes, obesity and related comorbidities. She designs translational dietary food and supplement interventions to further understand effects on metabolism and energy homeostasis, body composition, insulin resistance, oxidative stress and inflammation. Dr. Silver has completed several randomized controlled trials and has an active database of over 600 individuals with obesity and/or diabetes who are interested in participating in clinical research projects. Dr. Silver has trained over 500 registered dietitians in diet assessment methods. As Director of the Nutrition and Diet Assessment Core, she supervises a team of registered dietitians and research assistants who perform diet and nutrition assessments, nutrition education, nutrition counseling and nutrition therapy.
Dr. Rubina A Heptulla is a Professor of Pediatrics and Medicine, Albert Einstein College of Medicine. As Division Chief of Pediatric Endocrinology at The Children′s Hospital at Montefiore, Dr. Heptulla is transforming the division in many areas and is recruiting leading researchers in many areas of endocrinological research. An internationally recognized pediatric endocrinologist, Dr. Heptulla was awarded the McNair Scholar for Juvenile Diabetes by the Janice and Robert McNair Foundation. She is also the recipient of many grants from the Juvenile Diabetes Research Foundation and the National Institutes of Health (NIH). Her areas of research expertise encompass all aspects of
Dr. Rubina A Heptulla is a Professor of Pediatrics and Medicine, Albert Einstein College of Medicine. As Division Chief of Pediatric Endocrinology at The Children′s Hospital at Montefiore, Dr. Heptulla is transforming the division in many areas and is recruiting leading researchers in many areas of endocrinological research. An internationally recognized pediatric endocrinologist, Dr. Heptulla was awarded the McNair Scholar for Juvenile Diabetes by the Janice and Robert McNair Foundation. She is also the recipient of many grants from the Juvenile Diabetes Research Foundation and the National Institutes of Health (NIH). Her areas of research expertise encompass all aspects of diabetes, from the artificial pancreas project to the use of innovative therapies to treat both type 1 and 2 diabetes.
Dr. Akira Sugawara is a Professor in the Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine. His research interests include Research Molecular Biology of Nuclear Hormone Receptors, Etiology of High Blood Pressure, Pathophysiology of Diabetic Nephropathy, Gene Regulation of Aldosterone Synthesis, Epigenetics of Hypertension and Diabetes Mellitus.
Dr. Akira Sugawara is a Professor in the Department of Molecular Endocrinology, Tohoku University Graduate School of Medicine. His research interests include Research Molecular Biology of Nuclear Hormone Receptors, Etiology of High Blood Pressure, Pathophysiology of Diabetic Nephropathy, Gene Regulation of Aldosterone Synthesis, Epigenetics of Hypertension and Diabetes Mellitus.
Nachiappan Chockalingam is the Professor of Clinical Biomechanics at the Faculty of Health Sciences, Staffordshire University. Nachi directs the Biomechanics Facility and leads the Biomechanics team. He is also an Affiliate Professor at the Faculty of Health Sciences, University of Malta and a Visiting Professor at Sri Ramachandra University, India. He is a Chartered Engineer, a Chartered Scientist and a member of various professional organisations. Nachi was elected to and served as a member of the Engineering Group Board at the Institute of Physics and Engineering in Medicine and had been elected and served as the Secretary of Footwear
Nachiappan Chockalingam is the Professor of Clinical Biomechanics at the Faculty of Health Sciences, Staffordshire University. Nachi directs the Biomechanics Facility and leads the Biomechanics team. He is also an Affiliate Professor at the Faculty of Health Sciences, University of Malta and a Visiting Professor at Sri Ramachandra University, India. He is a Chartered Engineer, a Chartered Scientist and a member of various professional organisations. Nachi was elected to and served as a member of the Engineering Group Board at the Institute of Physics and Engineering in Medicine and had been elected and served as the Secretary of Footwear Biomechanics Group; a technical group of the International Society of Biomechanics. His research interests are in the general area of biomechanics and gait analysis. He currently leads several research projects in the area of understanding the design, manufacture and clinical intervention using orthoses, including a large European Union funded research project on Diabetic Foot and Footwear looking at the development of an integrated system for diabetic foot assessment.
Professor Roberto Ferrari works as Professor of Cardiology at the University of Ferrara and is Director of Cardiology at the Santa Anna University Hospital of Ferrara. He trained at the Bologna School of Medicine in Italy. Professor Ferrari is currently the President of European Heart for Children. His research interests concern the characterization of the molecular mechanisms of the ischemic and failing myocardium and the clinical treatment of myocardial ischemia and heart failure, with a particular emphasis on interdisciplinary and collaborative studies.
Professor Roberto Ferrari works as Professor of Cardiology at the University of Ferrara and is Director of Cardiology at the Santa Anna University Hospital of Ferrara. He trained at the Bologna School of Medicine in Italy. Professor Ferrari is currently the President of European Heart for Children. His research interests concern the characterization of the molecular mechanisms of the ischemic and failing myocardium and the clinical treatment of myocardial ischemia and heart failure, with a particular emphasis on interdisciplinary and collaborative studies.
Prof Andrew Collier is a Consultant Physician in General Medicine, Diabetes & Endocrinology and works at the University Hospital, Ayr in the West of Scotland. He trained in the Diabetes and Endocrinology in the Diabetes Unit in Edinburgh Royal Infirmary and in the MRC Blood Pressure in Glasgow. His research interests are varied and include hypertension, plus metabolic changes with vascular disease.
Prof Andrew Collier is a Consultant Physician in General Medicine, Diabetes & Endocrinology and works at the University Hospital, Ayr in the West of Scotland. He trained in the Diabetes and Endocrinology in the Diabetes Unit in Edinburgh Royal Infirmary and in the MRC Blood Pressure in Glasgow. His research interests are varied and include hypertension, plus metabolic changes with vascular disease.
Zhaoqian Liu, M.D, PhD supervisor, is currently the vice deans of Institute of Clinical Pharmacology at Central South University, and also director of Hunan Key Laboratory of Pharmacogenetics. He has been the senior visiting scholar at Munich University in Germany from 1996-1998, and the Postdoctoral Research Fellow at Department of Pharmacology and Toxicology of Indiana University School of Medicine in United State of America from 2002-2004. Professor Liu has got more than 15 national and province grants in recent five years. He has published 122 SCI papers on pharmacogenetics and pharmacogenomics research published in abroad journals include Pharmacogenetics and genomics, Nucleic
Zhaoqian Liu, M.D, PhD supervisor, is currently the vice deans of Institute of Clinical Pharmacology at Central South University, and also director of Hunan Key Laboratory of Pharmacogenetics. He has been the senior visiting scholar at Munich University in Germany from 1996-1998, and the Postdoctoral Research Fellow at Department of Pharmacology and Toxicology of Indiana University School of Medicine in United State of America from 2002-2004. Professor Liu has got more than 15 national and province grants in recent five years. He has published 122 SCI papers on pharmacogenetics and pharmacogenomics research published in abroad journals include Pharmacogenetics and genomics, Nucleic Acids Research, Clinical Pharmacol Ther etc. Professor Liu is now focusing on the research of basic and clinical applications of pharmacogenetics and pharmacogenomics on major diseases such as diabetes, epilepsy, and malignant tumor.
Carlo Maria Rotella graduated in Medicine and Surgery in 1974 at the University of Florence Medical School and achieved the Diploma of Specialist in Endocrinology in 1978 at the same University. In 1977 was appointed Research Assistant at the University of Florence; from 1985 he was Associated Professor in Endocrinology and from 2004 he is Full Professor of Endocrinology, in the Department of Biomedical, Experimental and Clinical Sciences at the University of Florence. He spent two periods or at the National Institutes of Health, Bethesda, Maryland, as Visiting Associate, andat the City of Hope National Medical Center, Duarte, California asVisiting
Carlo Maria Rotella graduated in Medicine and Surgery in 1974 at the University of Florence Medical School and achieved the Diploma of Specialist in Endocrinology in 1978 at the same University. In 1977 was appointed Research Assistant at the University of Florence; from 1985 he was Associated Professor in Endocrinology and from 2004 he is Full Professor of Endocrinology, in the Department of Biomedical, Experimental and Clinical Sciences at the University of Florence. He spent two periods or at the National Institutes of Health, Bethesda, Maryland, as Visiting Associate, andat the City of Hope National Medical Center, Duarte, California asVisiting Scientist. At present he is Director of Obesity Agency at the Careggi University Hospital. He was member of the Board of Directors of the Italian Society of Endocrinology, as well as of the Italian Society of Diabetology.He is Past-President of the Italian Society of Obesity. His topics of research are focused on Thyroid Diseases, Diabetes Mellitus, Obesity and Dyslipidemia.
As background, soon after I received my PhD in India in 1992, I began my earlier training as a post-doctoral fellow in Vanderbilt University, Nashville, TN. Later I have moved to UTMB, Galveston, TX where I worked as a post-doctoral fellow and Assistant Professor (non T-T) in the Department of Ob/Gyn (Oct 1994-2004) and Assistant Professor (T-T) in the Division of Gastroenterology (2004-2008). When I arrived in Nashville (2008), my appointment was as an Associate Professor (T-T) in the Department of Ob/Gyn at Meharry Medical College; I was also a member of the Center for Women's Health Research (CWHR). In
As background, soon after I received my PhD in India in 1992, I began my earlier training as a post-doctoral fellow in Vanderbilt University, Nashville, TN. Later I have moved to UTMB, Galveston, TX where I worked as a post-doctoral fellow and Assistant Professor (non T-T) in the Department of Ob/Gyn (Oct 1994-2004) and Assistant Professor (T-T) in the Division of Gastroenterology (2004-2008). When I arrived in Nashville (2008), my appointment was as an Associate Professor (T-T) in the Department of Ob/Gyn at Meharry Medical College; I was also a member of the Center for Women's Health Research (CWHR). In 2011, my primary appointment moved to the Department of Physiology because of my strong background in physiology, but I maintained my status as an active member of the CWHR. In 2012, I was given a secondary appointment in the School of Dentistry (SOD) and the title of Chairman, Oral Biology and Research. Since I organized a SOD course on 'Introduction to Clinical Research' and continue to foster collaborative faculty and student research projects. Recently, in Fall 2013 we have introduced 'Biomedical Integration Seminar Course' to Freshman Dental Students. This course will allow the students not only to learn how to integrate basic sciences into their dental clinical approach and patient care but also will help them to understand on how poor oral health can cause systemic diseases. For the past several years, I have been providing research training to post-doctoral fellows, research technicians, and junior faculty, and residents, medical and dental students. I have been funded with NIH and institutional grants as a PI or Co-Inv for the past 15 years. Research interests include Endocrinology, Gastrointestinal motility, Reproductive Physiology, Oral Bioloy and its relationship with systemic health, Menopause related health problems, Cell Biology, Diabetes & Obesity associated health complications.
Patrizio Tatti was born in Rome and graduated in Medicine at the age of 24. He spent 8 years in Emergency Medicine and Internal Medicine, and at the age of 32 was put in charge of a Center for Diabetes. At the age of 38 he was appointed chief of Endocrinology and Diabetes for a large facility of the Italian national health Service. Prof Tatti is the author of more than 140 papers in Medicine, and is reviewer for many international Journals and Editor for the Journal of Electrical and Computer Engineering and the International Journal of Endocrinology. He is
Patrizio Tatti was born in Rome and graduated in Medicine at the age of 24. He spent 8 years in Emergency Medicine and Internal Medicine, and at the age of 32 was put in charge of a Center for Diabetes. At the age of 38 he was appointed chief of Endocrinology and Diabetes for a large facility of the Italian national health Service. Prof Tatti is the author of more than 140 papers in Medicine, and is reviewer for many international Journals and Editor for the Journal of Electrical and Computer Engineering and the International Journal of Endocrinology. He is also consultant for many TV stations and was invited as a Key Opinion Leader in many Asian countries (China, Malaysia,Singapore, Taiwan), in India, and Greece He was also invited by the Ministry of Saudi Arabia to present the CME program 'Saudi Guidelines for the management of Type 2 Diabetes', in three main cities of the country. He is the President of the Italian Society of Hospital Diabetologists.
Dr. Edson received his Bachelors degree in Physiotherapy in 2001. He obtained his MD degree in 'Cellular and Structural Biology' from the Federal University of Vicosa (UFV), Brazil, in 2007, and his Ph.D. in 2013. He worked as a frontline clinician in both public and private settings for years.Since 2006, he works at the Department of Basic Sciences of the Federal University of Jequitinhonha and Mucuri Valleys, in Diamantina, Brazil with expertise in Morphology and Diabetes. His work and research activity is focused in studies of the cellular biology, diabetes and human anatomy. He is a Member of the
Dr. Edson received his Bachelors degree in Physiotherapy in 2001. He obtained his MD degree in 'Cellular and Structural Biology' from the Federal University of Vicosa (UFV), Brazil, in 2007, and his Ph.D. in 2013. He worked as a frontline clinician in both public and private settings for years.Since 2006, he works at the Department of Basic Sciences of the Federal University of Jequitinhonha and Mucuri Valleys, in Diamantina, Brazil with expertise in Morphology and Diabetes. His work and research activity is focused in studies of the cellular biology, diabetes and human anatomy. He is a Member of the Brazilian Society of Diabetes and Brazilian Society of Anatomy.
Xiangbing Wang, MD., Ph.D, is a Board Certified Physician in Internal Medicine and Endocrinology. He graduated from Hunan Medical University in 1986, and obtained his Ph.D in the fields of Physiology/Pharmacology from Oregon Health Science University, USA in 1994. He finished his postgraduate training in field of Endocrine Pharmacology at Yale University in 1996 and his 5-year clinical training in Internal Medicine and Endocrinology in Interfaith Medical Center, SUNY at Brooklyn in 2001. Currently, he is an Associate Professor of Medicine and Director of a research laboratory for metabolic disorders. He is an experienced clinician and a
Xiangbing Wang, MD., Ph.D, is a Board Certified Physician in Internal Medicine and Endocrinology. He graduated from Hunan Medical University in 1986, and obtained his Ph.D in the fields of Physiology/Pharmacology from Oregon Health Science University, USA in 1994. He finished his postgraduate training in field of Endocrine Pharmacology at Yale University in 1996 and his 5-year clinical training in Internal Medicine and Endocrinology in Interfaith Medical Center, SUNY at Brooklyn in 2001. Currently, he is an Associate Professor of Medicine and Director of a research laboratory for metabolic disorders. He is an experienced clinician and a principle investigator of several clinical trials, and is also is a member of the publication committee and clinical research committee of the American Association of Clinical Endocrinologist. He serves on the editorial board of several peer-review journals and has published more than 70 research articles. His major research interests are 1) the effects of thyroid and parathyroid disorders on mineral, carbohydrate and lipid metabolism and 2) diabetic medications, gender and ethnic differences in diabetic management.
Dr. Salehian, graduated from medical school from Tehran University in 1979, and during his residency training in Iran and later as postdoc fellow in France and latter in US retraining in endocrinology and Internal medicine, the fascination turned more toward practical steps to understand better this relationship that governs not only glucose metabolism but simultaneously prepare the ground for obesity, insulin resistance and inflammation as a process of diabetogenesis and atherosclerosis. His work in the field of metabolic syndrome was on the effect of pioglitazone on adipose tissue, prevention of carotid intima thickness and adiponectin; diabetogenesis in HIV infected
Dr. Salehian, graduated from medical school from Tehran University in 1979, and during his residency training in Iran and later as postdoc fellow in France and latter in US retraining in endocrinology and Internal medicine, the fascination turned more toward practical steps to understand better this relationship that governs not only glucose metabolism but simultaneously prepare the ground for obesity, insulin resistance and inflammation as a process of diabetogenesis and atherosclerosis. His work in the field of metabolic syndrome was on the effect of pioglitazone on adipose tissue, prevention of carotid intima thickness and adiponectin; diabetogenesis in HIV infected patient on Protease Inhibitors, predictive value of hyperglycemia post stem cell transplantation and development of acute GVHD and recently a first case report of detection of DNA of adenovirus- 36 in adipose tissue of a patient with unusual obesity as a possible promoter of this obesity. Other area of his interest is Islet Cells Transplantation and as an endocrinologist member of Islets cell transplantation team at city of Hope I am studying the role of thrombomodulin on early graft loss after the islet transplantation.
I am an MD/PhD and endocrinologist who has been working in the genetics of maturity-onset diabetes of the young (MODY), type 2 diabetes (T2D), and associated phenotypes. I graduated in Medicine and Surgery in 1992 and became an Endocrinologist in 1998 at the U. La Sapienza of Rome and obtained my PhD in 2003 at the U. Tor Vergata of Rome. I performed my research at U. of Chicago as JDFI Fellow (1995-1997), at Mass General Hospital (2000-2005) as a Rotary International Ambassador and NIH Training Fellow. As Instructor in Medicine at Harvard Medical School I taught/tutored Human Genetics of
I am an MD/PhD and endocrinologist who has been working in the genetics of maturity-onset diabetes of the young (MODY), type 2 diabetes (T2D), and associated phenotypes. I graduated in Medicine and Surgery in 1992 and became an Endocrinologist in 1998 at the U. La Sapienza of Rome and obtained my PhD in 2003 at the U. Tor Vergata of Rome. I performed my research at U. of Chicago as JDFI Fellow (1995-1997), at Mass General Hospital (2000-2005) as a Rotary International Ambassador and NIH Training Fellow. As Instructor in Medicine at Harvard Medical School I taught/tutored Human Genetics of Complex Disorders, Endocrinology, and Chemistry and Cell Biology. As Assistant Professor in Medicine, Molecular & Cellular Physiology and Public Health Sciences at Penn State U. M.S. Hershey Medical Center (2006-2013), I continued my research and have been Faculty Committee member of the Penn State U. PhD Intercollege Graduate Degree Program in Physiology, Genetics, Biomedical Sciences Program, and of the MD/PhD Program. At Penn State I taught endocrinology, diabetes, genetics of monogenic and complex disorders. Since 2008, I am an Adjunct Associate Professor in Biology at Temple University's College of Science and Technology in Philadelphia. Since August 2013 I am board certified in Internal Medicine under the special candidacy pathway. I am ABIM eligible to take the Endocrine Board and plan to take it this November 2014. I am since 2014 Associate Professor in Medicine at the University of Florida, Jacksonville.
Dr. Lakshman Segar is an Associate Professor in the Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, USA. The research projects in his laboratory are focused on dysregulated metabolic and signaling pathways that contribute to exaggerated vascular smooth muscle cell (VSMC) proliferation in the context of atherosclerosis and restenosis after angioplasty. Using human aortic VSMCs in culture, his research team investigates how altered glucose metabolism regulates key proliferative signaling pathways. In conjunction with these studies, they also examine the roles of AMP-activated protein kinase (AMPK) and PI 3-kinase/Akt signaling toward VSMC phenotypic changes. In vivo studies
Dr. Lakshman Segar is an Associate Professor in the Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, USA. The research projects in his laboratory are focused on dysregulated metabolic and signaling pathways that contribute to exaggerated vascular smooth muscle cell (VSMC) proliferation in the context of atherosclerosis and restenosis after angioplasty. Using human aortic VSMCs in culture, his research team investigates how altered glucose metabolism regulates key proliferative signaling pathways. In conjunction with these studies, they also examine the roles of AMP-activated protein kinase (AMPK) and PI 3-kinase/Akt signaling toward VSMC phenotypic changes. In vivo studies utilize a mouse model of arterial injury to investigate how insulin resistance and altered glucose metabolism contribute to exaggerated neointima formation. Furthermore, in vitro and in vivo studies investigate the vasoprotective effects of antidiabetic drugs including metformin, pioglitazone, and incretins.
Alissa R. Segal, PharmD, RPh, CDE, CDTC, FCCP is an Associate Professor, MCPHS University and clinical pharmacist at the Joslin Diabetes Center, Boston, MA, (2007-). After several years at the University of New Mexico, Dr. Segal joined MCPHS University and established clinical pharmacy services at the Joslin. Her research focus on the care of adults with diabetes has led to numerous publications, on diabetes in older adults and highly-concentrated insulin, and book chapters in the Joslin Deskbook, Endocrine and Metabolic Medical Emergencies, and Geriatric Diabetes. She is a fellow of the American College of Clinical Pharmacy (ACCP). She serves on
Alissa R. Segal, PharmD, RPh, CDE, CDTC, FCCP is an Associate Professor, MCPHS University and clinical pharmacist at the Joslin Diabetes Center, Boston, MA, (2007-). After several years at the University of New Mexico, Dr. Segal joined MCPHS University and established clinical pharmacy services at the Joslin. Her research focus on the care of adults with diabetes has led to numerous publications, on diabetes in older adults and highly-concentrated insulin, and book chapters in the Joslin Deskbook, Endocrine and Metabolic Medical Emergencies, and Geriatric Diabetes. She is a fellow of the American College of Clinical Pharmacy (ACCP). She serves on the NIH National Kidney Disease Education ProgramPharmacy Workgroup, ACCP Endocrine and Geriatric Practice and Research Networks, and theNational Certification Board of Diabetes Education Outreach Committee. Dr. Segal completed her Doctor of Pharmacy at Drake University and post-doctorate residencies at the Medical Center at Princeton and the Medical University of South Carolina.
Yebin Jiang, MD, PhD, obtained his PhD at Catholic University of Leuven School of Medicine in Belgium after his medical education in China. He also did visiting fellowships in Bone and Joint Center of Henry Ford Hospital and in Radiobiology Division of University of Utah. After that, he joined faculty at University of California San Francisco as a assistant professor, promoted to associate professor, and stayed there for over 10 years. He then relocated to University of Michigan in Ann Arbor, as a director of a research laboratory in 2006. Dr. Jiang has conducted basic, translational, and clinical research on
Yebin Jiang, MD, PhD, obtained his PhD at Catholic University of Leuven School of Medicine in Belgium after his medical education in China. He also did visiting fellowships in Bone and Joint Center of Henry Ford Hospital and in Radiobiology Division of University of Utah. After that, he joined faculty at University of California San Francisco as a assistant professor, promoted to associate professor, and stayed there for over 10 years. He then relocated to University of Michigan in Ann Arbor, as a director of a research laboratory in 2006. Dr. Jiang has conducted basic, translational, and clinical research on bone biology, metabolic bone diseases, osteoporosis, arthritis, neurological disorders, and imaging, and published over 100 peer-reviewed papers.
Dr. Michael R. Kushnick, Ph.D., HFS is an Associate Professor of Exercise Physiology, School of Applied Health Sciences and Wellness, College of Health Sciences and ProfessionsOhio University. He also hold the positions of Graduate Coordinator of Exercise Physiology, Co-Director, Exercise Physiology Laboratory, Director, Exercise Biochemistry Laboratory, 2011-2014 Academic Fellow, College of Health Sciences and Professions, 2014 Past-President, Midwest American College of Sports Medicine. His research keywords include Blood lipids, Triglycerides, Insulin Resistance, Lipoproteins, Metabolism.
Dr. Michael R. Kushnick, Ph.D., HFS is an Associate Professor of Exercise Physiology, School of Applied Health Sciences and Wellness, College of Health Sciences and ProfessionsOhio University. He also hold the positions of Graduate Coordinator of Exercise Physiology, Co-Director, Exercise Physiology Laboratory, Director, Exercise Biochemistry Laboratory, 2011-2014 Academic Fellow, College of Health Sciences and Professions, 2014 Past-President, Midwest American College of Sports Medicine. His research keywords include Blood lipids, Triglycerides, Insulin Resistance, Lipoproteins, Metabolism.
Dr. Yunhua Li Muller graduated from University of Arizona with a Ph.D. degree in physiology and received post-doctoral training from Mayo Clinic Scottsdale and Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), NIH. She currently serves as a Senior Research Scientist at NIDDK, NIH. Her research interests focus on studying the molecular mechanisms of diabetes and obesity in transgenic mice and humans using molecular biology and genomic tools. She has been working on finding the genetic defects involved in type 2 diabetes, obesity or metabolic risks such as insulin resistance and beta-cell
Dr. Yunhua Li Muller graduated from University of Arizona with a Ph.D. degree in physiology and received post-doctoral training from Mayo Clinic Scottsdale and Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), NIH. She currently serves as a Senior Research Scientist at NIDDK, NIH. Her research interests focus on studying the molecular mechanisms of diabetes and obesity in transgenic mice and humans using molecular biology and genomic tools. She has been working on finding the genetic defects involved in type 2 diabetes, obesity or metabolic risks such as insulin resistance and beta-cell failure related to these diseases in Pima Indians, a population with extremely high rates of these diseases.
Dr. Yoshiyuki Ban is the Associate Professor at Teikyo University Chiba Medical Center′s Department of Medicine. Dr. Ban received his medical degree from the Showa University School of Medicine, Japan. He trained in Internal Medicine and in Endocrinology at Showa University Hospital, Japan. Dr. Ban stayed in Showa University after his training, joining the faculty of the Showa University Karasuyama Hospital′s Department of Medicine in 2004. Dr. Ban joined Showa University School of Medicine in April of 2008 as Assistant Professor of Medicine.
Dr. Yoshiyuki Ban is the Associate Professor at Teikyo University Chiba Medical Center′s Department of Medicine. Dr. Ban received his medical degree from the Showa University School of Medicine, Japan. He trained in Internal Medicine and in Endocrinology at Showa University Hospital, Japan. Dr. Ban stayed in Showa University after his training, joining the faculty of the Showa University Karasuyama Hospital′s Department of Medicine in 2004. Dr. Ban joined Showa University School of Medicine in April of 2008 as Assistant Professor of Medicine.
I received Ph.D. from Banaras Hindu University, India in 2006. I was trained as postdoctoral from Emory University, Atlanta, and University of Louisville, Kentucky, USA. I was promoted to Assistant Professor in 2010 at Department of Physiology & Biophysics, University of Louisville. I joined Department of Cellular and Integrative Physiology, University of Nebraska Medical Center (UNMC), Omaha in the year 2013. My major interest is to understand the mechanism of structural and functional cardiac remodeling in diabetics with the goal to develop intervention tool. Recently, miRNAs have emerged as biomarker and therapeutic target for cardiovascular and other diseases. My research
I received Ph.D. from Banaras Hindu University, India in 2006. I was trained as postdoctoral from Emory University, Atlanta, and University of Louisville, Kentucky, USA. I was promoted to Assistant Professor in 2010 at Department of Physiology & Biophysics, University of Louisville. I joined Department of Cellular and Integrative Physiology, University of Nebraska Medical Center (UNMC), Omaha in the year 2013. My major interest is to understand the mechanism of structural and functional cardiac remodeling in diabetics with the goal to develop intervention tool. Recently, miRNAs have emerged as biomarker and therapeutic target for cardiovascular and other diseases. My research work focuses on finding the candidate miRNAs involved in heart failure especially diabetic cardiomyopathy and using them for ameliorating cardiac dysfunction. Additionally, we are also investigating the role of MMP9, beta2-adrenergic receptors, hydrogen sulfide and homocysteine on miRNA regulation, extracellular matrix remodeling, impaired contractility of cardiomyocytes and heart failure using in vivo, ex-vivo and in vitro approaches. The role of miR-133 as epi-miR, and regulator of cardiac autophagy, and impact of ablation of MMP9 on stem cell survival and differentiation are two new promising areas we are currently pursuing to dissect the mechanism of heart failure at different level. I have been funded with American Heart Association, Beginning-Grant-in-Aid from 2011-13. Currently, I have NIH, RO1 grants.
Hiroaki Satoh, M.D., Ph.D. is an Associate Professor in the Department of Nephrology, Hypertension, Diabetology, Endocrinology, and Metabolism at Fukushima Medical University. Dr. Satoh received his M.D. from Akita University and his Ph.D. from University of Tokyo Graduate School of Medicine. Before coming to Fukushima Medical university, he was a resident in Internal Medicine at the University of Tokyo hospital, a graduate student at University of Tokyo Graduate School of Medicine, a research fellow in Jerrold M Olefskys lab at University of California, San Diego. Dr. Satoh has been on the Fukushima Medical University faculty since 2004. His research focuses
Hiroaki Satoh, M.D., Ph.D. is an Associate Professor in the Department of Nephrology, Hypertension, Diabetology, Endocrinology, and Metabolism at Fukushima Medical University. Dr. Satoh received his M.D. from Akita University and his Ph.D. from University of Tokyo Graduate School of Medicine. Before coming to Fukushima Medical university, he was a resident in Internal Medicine at the University of Tokyo hospital, a graduate student at University of Tokyo Graduate School of Medicine, a research fellow in Jerrold M Olefskys lab at University of California, San Diego. Dr. Satoh has been on the Fukushima Medical University faculty since 2004. His research focuses is to understand the molecular and cellular mechanisms of insulin resistance.
Dr. Tomiyasu Murata is an Associate Professor (2009-present), Lecturer (2006-2008), Assistant Professor (1998-2005) in the Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Japan; Assistant Professor(1996-1997) in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan; Research Associate (1994-1995) in Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan. He received a Ph.D. in Graduate School of Pharmacy, Division of Pharmaceutical Sciences, Meijo University (1993, Japan). His research interests includes: Endoplasmic reticulum stress response of pancreatic beta-cells and neuronal cells; Role of novel calcium-binding protein regucalcin in adipogenesis, osteoclastogenesis, and
Dr. Tomiyasu Murata is an Associate Professor (2009-present), Lecturer (2006-2008), Assistant Professor (1998-2005) in the Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, Japan; Assistant Professor(1996-1997) in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan; Research Associate (1994-1995) in Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan. He received a Ph.D. in Graduate School of Pharmacy, Division of Pharmaceutical Sciences, Meijo University (1993, Japan). His research interests includes: Endoplasmic reticulum stress response of pancreatic beta-cells and neuronal cells; Role of novel calcium-binding protein regucalcin in adipogenesis, osteoclastogenesis, and osteoblastogenesis; Pathogenesis oftype II diabetes mellitus; Development of pharmacological lead compounds isolated from natural resource for therapy of obesity, cancer, and neurodegenerative disease.
Dr. Petrica graduated from the Faculty of Medicine, 'Victor Babes' University of Medicine and Pharmacy,Timişoara, Romania, where she is currently associate professor, senior consultant in internal medicine and nephrology. She completed her postgraduate degree on 'Urinary tract infection associated to renal diseases' and gained a fellowship in nephrology at the Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, under the tutorship of Prof. Dr JHM Berden. Her fields of interest include clinical nephrology, diabetic nephropathy, connective tissue diseases, vasculitis, and chronic kidney disease (CKD).
Dr. Petrica graduated from the Faculty of Medicine, 'Victor Babes' University of Medicine and Pharmacy,Timişoara, Romania, where she is currently associate professor, senior consultant in internal medicine and nephrology. She completed her postgraduate degree on 'Urinary tract infection associated to renal diseases' and gained a fellowship in nephrology at the Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, under the tutorship of Prof. Dr JHM Berden. Her fields of interest include clinical nephrology, diabetic nephropathy, connective tissue diseases, vasculitis, and chronic kidney disease (CKD).
Dr. Santulli is a Physician-Scientist currently working at Columbia University Medical Center (Russ Berrie Medical Science Pavilion) in Manhattan, New York, NY. He authored over 100 publications in the medical field, including books and book chapters. He serves as Associate Editor for several high impact factor Journals in the fields of cardiovascular medicine and metabolic disorders. His main research interests include hypertension, diabetes mellitus,Aging, Angiogenesis, Myocardial infarction, Heart failure, Atrial fibrillation, Cardiac hypertrophy, vascular disease, Calcium handling, microRNA, Calcium signaling, cardiac resynchronization therapy, adrenergic receptors, Angioplasty, restenosis, insulin release, mitochondria, insulin resistance.
Dr. Santulli is a Physician-Scientist currently working at Columbia University Medical Center (Russ Berrie Medical Science Pavilion) in Manhattan, New York, NY. He authored over 100 publications in the medical field, including books and book chapters. He serves as Associate Editor for several high impact factor Journals in the fields of cardiovascular medicine and metabolic disorders. His main research interests include hypertension, diabetes mellitus,Aging, Angiogenesis, Myocardial infarction, Heart failure, Atrial fibrillation, Cardiac hypertrophy, vascular disease, Calcium handling, microRNA, Calcium signaling, cardiac resynchronization therapy, adrenergic receptors, Angioplasty, restenosis, insulin release, mitochondria, insulin resistance.
Yun Yan, MD, is board-certified in pediatrics and pediatric endocrinology. She joined Children′s Mercy Hospital in June 2011 after she completed her pediatric endocrinology fellowship training at the University of North Carolina in Chapel Hill. She has an appointment as an assistant professor of pediatrics and endocrinology at University of Missouri- Kansas city, MO (UMKC) and University of Kansas, KS (KU). She is a member of Pediatric Endocrine Society, Endocrine Society, American Diabetes Association and Midwest Society for Pediatric Research. She has published more than 15 peer-reviewed scientific papers, including papers in Cell and Science.
Yun Yan, MD, is board-certified in pediatrics and pediatric endocrinology. She joined Children′s Mercy Hospital in June 2011 after she completed her pediatric endocrinology fellowship training at the University of North Carolina in Chapel Hill. She has an appointment as an assistant professor of pediatrics and endocrinology at University of Missouri- Kansas city, MO (UMKC) and University of Kansas, KS (KU). She is a member of Pediatric Endocrine Society, Endocrine Society, American Diabetes Association and Midwest Society for Pediatric Research. She has published more than 15 peer-reviewed scientific papers, including papers in Cell and Science. Dr. Yan participates in both translational and clinical researches and her current research interests include micro and macrovascular complications and pancreatic beta cell dysfunction induced by hyperglycemia and glycemic variability.
Cathryn Kolka obtained her PhD at the University of Tasmania in Australia, with a focus on glucose uptake in skeletal muscle, including the transport of glucose across the endothelial barrier, the effect of exercise on glucose metabolism, and the hemodynamic effects of insulin and other hormones. After completing her post-doctoral training at University of Southern California, she is now an assistant professor in the Diabetes and Obesity Research Institute at Cedars-Sinai Medical Center in Los Angeles. Her current focus is the access of insulin to the skeletal muscle interstitium in health and disease, and is interested in targets
Cathryn Kolka obtained her PhD at the University of Tasmania in Australia, with a focus on glucose uptake in skeletal muscle, including the transport of glucose across the endothelial barrier, the effect of exercise on glucose metabolism, and the hemodynamic effects of insulin and other hormones. After completing her post-doctoral training at University of Southern California, she is now an assistant professor in the Diabetes and Obesity Research Institute at Cedars-Sinai Medical Center in Los Angeles. Her current focus is the access of insulin to the skeletal muscle interstitium in health and disease, and is interested in targets and treatments that may augment this access and thus help to treat insulin resistance. This can include aspects of muscle perfusion, cellular insulin sensitivity in vivo, and endothelial function in muscle and other tissues. The concept that manipulating the vascular system can treat metabolic disease forms the basis of her studies.
Dr. Xinfu Guan is an Assistant Professor of Nutrition and Endocrinology in Departments of Pediatrics and Medicine, Baylor College of Medicine; and a Nutrition Scientist (Principal Investigator) at the USDA Children′s Nutrition Research Center. After he obtained his Ph.D. degree from Michigan State University. His research interests are to elucidate the gut-brain-liver axis in the control of energy balance and glycemic control and to ameliorate glucose intolerance and insulin resistance in obesity and diabetes.
Dr. Xinfu Guan is an Assistant Professor of Nutrition and Endocrinology in Departments of Pediatrics and Medicine, Baylor College of Medicine; and a Nutrition Scientist (Principal Investigator) at the USDA Children′s Nutrition Research Center. After he obtained his Ph.D. degree from Michigan State University. His research interests are to elucidate the gut-brain-liver axis in the control of energy balance and glycemic control and to ameliorate glucose intolerance and insulin resistance in obesity and diabetes.
Dr Soon Song is a Consultant Physician and Diabetologist and Honorary Senior Clinical Lecturer at Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, UK. He is a full time NHS consultant who is actively involved in the care of patients with diabetes and general medical conditions. His main research interest is diabetes-related complications and cardiovascular risk in young-onset type 2 diabetes in adults and has published original studies in this area in the UK population. He is also involved in postgraduate training and examinations, in particular MRCP(UK) and Specialty Certificate Examination in Diabetes and Endocrinology.
Dr Soon Song is a Consultant Physician and Diabetologist and Honorary Senior Clinical Lecturer at Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, UK. He is a full time NHS consultant who is actively involved in the care of patients with diabetes and general medical conditions. His main research interest is diabetes-related complications and cardiovascular risk in young-onset type 2 diabetes in adults and has published original studies in this area in the UK population. He is also involved in postgraduate training and examinations, in particular MRCP(UK) and Specialty Certificate Examination in Diabetes and Endocrinology.
Dr. Vimal Karani is a Lecturer in Nutrigenetics at the University of Reading, UK. He also holds appointment as an Honorary Lecturer in Genetic Epidemiology at the University College London. He undertook his post-doctoral training at the University of Cambridge, UK. Dr. Vimal Karani has an interdisciplinary academic background, with qualifications from Medical Genetics, Bioinformatics, Molecular Biology and Genetic Epidemiology. His primary research interests focus on the investigation of gene-nutrient interactions on metabolic- and cardiovascular disease- related outcomes using combined approaches from genetic epidemiology, statistical genetics and molecular biology. His long term goal is to use the findings from observational
Dr. Vimal Karani is a Lecturer in Nutrigenetics at the University of Reading, UK. He also holds appointment as an Honorary Lecturer in Genetic Epidemiology at the University College London. He undertook his post-doctoral training at the University of Cambridge, UK. Dr. Vimal Karani has an interdisciplinary academic background, with qualifications from Medical Genetics, Bioinformatics, Molecular Biology and Genetic Epidemiology. His primary research interests focus on the investigation of gene-nutrient interactions on metabolic- and cardiovascular disease- related outcomes using combined approaches from genetic epidemiology, statistical genetics and molecular biology. His long term goal is to use the findings from observational studies to carry out human intervention studies with a view towards developing industrial collaborations to facilitate 'Personalised Nutrition'. He is also a lead study co-ordinator of a large international collaboration (D-CarDia), where he focuses on establishing the causal relationship between 25-hydroxyvitamin D and cardiovascular disease-related outcomes using Mendelian Randomization analysis.
Tao Cai, MD/PhD, is Staff Scientist at NIDCR, NIH, Bethesda, Maryland, USA (2001-); Visiting professor in Chinese Academy of Sciences at Beijing. Dr. Cai is interested in understanding how insulin production and secretion in pancreatic islet beta cells are regulated by vesicle-associated proteins and transcription factors. In recent years, Dr. Caihas applied a combination of classical genetic approaches and novel next-generation sequencing technique to identify and characterize the genes that cause human diseases, many of the mutations are associated with uncharacterized rare disorders.
Tao Cai, MD/PhD, is Staff Scientist at NIDCR, NIH, Bethesda, Maryland, USA (2001-); Visiting professor in Chinese Academy of Sciences at Beijing. Dr. Cai is interested in understanding how insulin production and secretion in pancreatic islet beta cells are regulated by vesicle-associated proteins and transcription factors. In recent years, Dr. Caihas applied a combination of classical genetic approaches and novel next-generation sequencing technique to identify and characterize the genes that cause human diseases, many of the mutations are associated with uncharacterized rare disorders.
He is currently the Reader and Honorary Consultant Physician in Academic Endocrinology, Diabetes and metabolism department at University of Hull, UK. He received his specialist training in Endocrinology initially at Aberdeen and subsequently in the Yorkshire Deanery. He did his postgraduate research at the University of Hull, United Kingdom. He was appointed Senior Lecturer in 2009 at the University of Hull and became a Reader in 2012. He has extensive clinical trials experience in diabetes. He is currently the principal investigator for public and commercially funded diabetes and metabolism studies in Hull, UK. He has
He is currently the Reader and Honorary Consultant Physician in Academic Endocrinology, Diabetes and metabolism department at University of Hull, UK. He received his specialist training in Endocrinology initially at Aberdeen and subsequently in the Yorkshire Deanery. He did his postgraduate research at the University of Hull, United Kingdom. He was appointed Senior Lecturer in 2009 at the University of Hull and became a Reader in 2012. He has extensive clinical trials experience in diabetes. He is currently the principal investigator for public and commercially funded diabetes and metabolism studies in Hull, UK. He has published several peer reviewed publications in this field. He is also actively involved in the clinical management of patients with Diabetes and Endocrinology
Dr. Ando, M.D., Ph.D., is an Assistant Professor of the Division of Endocrinology and Metabolism in Nagasaki University Hospital. He worked with Dr. Terry F. Davies lab in Mount Sinai School of Medicine from 2000 to 2005 mainly focusing on generation of monoclonal antibodies which stimulate thyrotropin receptor in the thyroid gland. His current research interests include clinical application of GLP-1 analogues to diabetic patients with specific clinical background and risk factors for adverse effects of radioiodine therapy for advanced thyroid cancer.
Dr. Ando, M.D., Ph.D., is an Assistant Professor of the Division of Endocrinology and Metabolism in Nagasaki University Hospital. He worked with Dr. Terry F. Davies lab in Mount Sinai School of Medicine from 2000 to 2005 mainly focusing on generation of monoclonal antibodies which stimulate thyrotropin receptor in the thyroid gland. His current research interests include clinical application of GLP-1 analogues to diabetic patients with specific clinical background and risk factors for adverse effects of radioiodine therapy for advanced thyroid cancer.
Debra Nanan, BAppSc (Queensland University of Technology), MPH (Johns Hopkins), Certificate in Management for International Public Health (Emory), is Vice President, Pacific Health & Development Sciences Inc., a health systems research and development consulting firm based in Victoria BC, Canada. She is an Adjunct Assistant Professor at the School of Public Health and Social Policy, University of Victoria, and has also supported research at the Centre for Leadership and Research, Royal Roads University, Victoria.She maintains a focus on public health practice, epidemiological design and analysis of population-based interventions, disease prevention, and international and global public health.
Debra Nanan, BAppSc (Queensland University of Technology), MPH (Johns Hopkins), Certificate in Management for International Public Health (Emory), is Vice President, Pacific Health & Development Sciences Inc., a health systems research and development consulting firm based in Victoria BC, Canada. She is an Adjunct Assistant Professor at the School of Public Health and Social Policy, University of Victoria, and has also supported research at the Centre for Leadership and Research, Royal Roads University, Victoria.She maintains a focus on public health practice, epidemiological design and analysis of population-based interventions, disease prevention, and international and global public health.
Dr Amirreza Haghighi is a genetic scientist at Toronto General Hospital, University of Toronto. His research interests focus on studying the genetic basis of diabetes, obesity and hereditary kidney diseases. Dr Haghighi is using state of the art technologies such as high throughput genotyping approaches (including GWAS and linkage analysis) and next generation sequencing to investigate the genetic basis of these diseases with the ultimate aim of translating the basic research discoveries into better diagnostics and improved management strategies. Dr Haghighi is also actively involved in science-advancement projects. He sits on advisory board of the Network for Knowledge and Innovation
Dr Amirreza Haghighi is a genetic scientist at Toronto General Hospital, University of Toronto. His research interests focus on studying the genetic basis of diabetes, obesity and hereditary kidney diseases. Dr Haghighi is using state of the art technologies such as high throughput genotyping approaches (including GWAS and linkage analysis) and next generation sequencing to investigate the genetic basis of these diseases with the ultimate aim of translating the basic research discoveries into better diagnostics and improved management strategies. Dr Haghighi is also actively involved in science-advancement projects. He sits on advisory board of the Network for Knowledge and Innovation (NIKI).
Dr. Omorogieva Ojo is a Senior Lecturer in primary care at the University of Greenwich, London. He is the coordinator of the Diabetes Care and Management course for post registration nurses and Patient Pathways of Care for pre-registration participants. He teaches diabetes and nutrition related topics in different courses across the School of Health and Social care and conducts study days in collaboration with partner organisations. His research interests include Diabetes, Structured Education in Diabetes for Ethnic Minorities, Evaluation of the Glycaemic index of some carbohydrate rich ethnic minority foods in the UK, Vitamin D and diabetes.
Dr. Omorogieva Ojo is a Senior Lecturer in primary care at the University of Greenwich, London. He is the coordinator of the Diabetes Care and Management course for post registration nurses and Patient Pathways of Care for pre-registration participants. He teaches diabetes and nutrition related topics in different courses across the School of Health and Social care and conducts study days in collaboration with partner organisations. His research interests include Diabetes, Structured Education in Diabetes for Ethnic Minorities, Evaluation of the Glycaemic index of some carbohydrate rich ethnic minority foods in the UK, Vitamin D and diabetes.
Thomas Bouckenooghe, PhD, is an assistant professor of molecular endocrinology at the catholic University of Louvain (Belgium). After the completion of his PhD in the lab of cell therapy of diabetes in Lille where he was doing human pancreatic islet isolation for engraftment in type 1 diabetic patients, he moved in several well-known European research labs to complete his training and to increase his knowledge on the natural history of the different forms of diabetes. His resrach interests include fetal programming of metabolic syndrome by modification of maternal feeding, fetal programming effect of maternal gestational diabetes, placental biology, mesenchymal stem
Thomas Bouckenooghe, PhD, is an assistant professor of molecular endocrinology at the catholic University of Louvain (Belgium). After the completion of his PhD in the lab of cell therapy of diabetes in Lille where he was doing human pancreatic islet isolation for engraftment in type 1 diabetic patients, he moved in several well-known European research labs to complete his training and to increase his knowledge on the natural history of the different forms of diabetes. His resrach interests include fetal programming of metabolic syndrome by modification of maternal feeding, fetal programming effect of maternal gestational diabetes, placental biology, mesenchymal stem cells biology and differentiation and beta-cell reprogramming.
All articles are fully peer reviewed, free to access and can be downloaded from our ClinMed archive.
Clinical Medical Image Library: 93.51
International Journal of Critical Care and Emergency Medicine: 92.83
International Journal of Sports and Exercise Medicine: 91.84
International Journal of Womens Health and Wellness: 91.79
Journal of Musculoskeletal Disorders and Treatment: 91.73
Journal of Geriatric Medicine and Gerontology: 91.55
Journal of Infectious Diseases and Epidemiology: 91.55
Clinical Medical Reviews and Case Reports: 91.40
International Archives of Nursing and Health Care: 90.87
International Journal of Ophthalmology and Clinical Research: 90.80
International Archives of Urology and Complications: 90.73
Journal of Clinical Nephrology and Renal Care: 90.33
Journal of Family Medicine and Disease Prevention: 89.99
Journal of Clinical Gastroenterology and Treatment: 89.54
Journal of Dermatology Research and Therapy: 89.34
International Journal of Clinical Cardiology: 89.24
International Journal of Radiology and Imaging Technology: 88.88
Obstetrics and Gynaecology Cases - Reviews: 88.42
International Journal of Blood Research and Disorders: 88.22
International Journal of Diabetes and Clinical Research: 87.97